NewGenIvf (NIVF) Common Equity (2022 - 2025)

NewGenIvf has disclosed Common Equity across 4 years of filings, most recently posting $26.0 million for Q4 2025.

• In Q4 2025, Common Equity rose 1853.78% year-over-year to $26.0 million; the TTM figure through Dec 2025 stood at $26.0 million (up 1853.78% YoY), while the FY2025 annual figure was $26.0 million, up 1853.78% from the prior year.
• Common Equity declined to $26.0 million in Q4 2025, from $28739.3 billion in the prior quarter.
• Over the last five years, Common Equity for NIVF reached as high as $28739.3 billion in Q3 2025 and fell as low as -$1.5 million in Q4 2024.
• The 4-year median for Common Equity is $6.0 million (2023), against an average of $4789.9 billion.
• Annual changes were most pronounced in 2023 — Common Equity jumped 3123.54% — and 2024, when it sank 145.65%.
• A 4-year view of Common Equity shows it stood at $100683.0 in 2022, then surged by 3123.54% to $3.2 million in 2023, then slumped by 145.65% to -$1.5 million in 2024, then soared by 1853.78% to $26.0 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $26.0 million, $28739.3 billion, and $8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.